Randy F. Sweis, MD

genitourinary oncologist and translational scientist

University of Chicago

Published Articles (1)

Kidney Cancer Treatment Diversifies: Dual Immunotherapy, HIF-2α Inhibition, and TKI-Free Intervals

August 28, 2026

Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.